MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-15-2026
GeoVax Labs Operating Expenses 2011-2026 | GOVX
Annual Operating Expenses GeoVax Labs
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.1 M | 29.1 M | 26.7 M | 14.1 M | 19.1 M | - | 3.55 M | 3.53 M | 3.25 M | 4.1 M | 3.12 M | 3.62 M | 4.71 M | 4.8 M | 7.25 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.1 M | 3.12 M | 10.8 M |
Quarterly Operating Expenses GeoVax Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.37 M | 6.27 M | 7.04 M | - | 8.64 M | 5.36 M | 5.88 M | - | 8.6 M | 6.18 M | 4.27 M | - | 3.97 M | 2.24 M | 2.51 M | - | 1.98 M | 1.57 M | 1.67 M | - | 852 K | 889 K | 1.31 M | - | 759 K | 864 K | 1.07 M | - | 1.02 M | 731 K | 844 K | - | 838 K | 870 K | 844 K | - | 905 K | 742 K | 1.34 M | - | 714 K | 750 K | 805 K | - | 837 K | 861 K | 805 K | - | 1.2 M | 969 K | 1.49 M | - | 936 K | 1.2 M | 1.59 M | - | 1.67 M | 1.96 M | 1.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.64 M | 714 K | 2.31 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.88 | 3.89 % | $ 9.34 B |  Australia |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 323.44 | -2.98 % | $ 42.4 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 7.93 | 6.81 % | $ 78.4 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.93 | 1.15 % | $ 1.03 B | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.71 | -0.63 % | $ 766 M | Britain |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.54 | 4.12 % | $ 356 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 101.62 | 2.16 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
64.6 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.22 | -0.59 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.83 | -3.05 % | $ 3.03 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.54 | 3.02 % | $ 410 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 33.61 | -0.77 % | $ 2.23 B | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.72 | -1.09 % | $ 1.21 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |